Get the Stockscreener App
1.15
4.17%
-0.05
After Hours:
1.26
0.11
+9.57%
Cadrenal Therapeutics Inc stock is traded at $1.15, with a volume of 221.60K.
It is down -4.17% in the last 24 hours and down -24.84% over the past month.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
See More
Previous Close:
$1.20
Open:
$1.25
24h Volume:
221.60K
Relative Volume:
0.53
Market Cap:
$4.10M
Revenue:
-
Net Income/Loss:
$-11.89M
P/E Ratio:
-0.2042
EPS:
-5.6317
Net Cash Flow:
$-10.96M
1W Performance:
+7.48%
1M Performance:
-24.84%
6M Performance:
-78.78%
1Y Performance:
-91.90%
1-Day Range:
$1.13
$1.25
1-Week Range:
$1.06
$1.355
52-Week Range:
$1.00
$14.64
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
1.15 | 4.10M | 0 | -11.89M | -10.96M | -5.6317 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
Cadrenal Therapeutics CEO to Present at Lytham Partners Fall 2026 Investor Conference - quiverquant.com
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference - GlobeNewswire
Cadrenal Therapeutics (CVKD) Slips 4.46% to $1.07, Drifting Toward Lower SupportSystematic Flow - dars.gov.et
Cadrenal Therapeutics Inc (CVKD) Stock Price, Quote, News & History - benzinga.com
Cadrenal Therapeutics announces up to $8.8M private placement - scanx.trade
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference - Yahoo Finance
Cadrenal Therapeutics advances CAD-1005 Phase 3 pathway - TipRanks
Cadrenal Therapeutics (CVKD) Advances Phase 3 Trial Protocol, Fa - GuruFocus
Cadrenal Therapeutics Announces FDA Alignment on Phase 3 Primary Endpoint for CAD-1005 HIT Study - Quiver Quantitative
FDA agrees to a placebo trial for a drug aimed at a blood reaction affecting 50,000 yearly - Stock Titan
CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise - Yahoo Finance
Cadrenal's CAD-1005 cuts thrombotic events by over 25% in Phase 2 - scanx.trade
Cadrenal (CVKD) Results Check: EPS Clears the Reported Estimate; After Results: Shares Move 4.09% Down on the DayEarnings Recovery Stocks - dars.gov.et
Cadrenal (CVKD) Latest Earnings Reading: The Bottom-Line Figure Beats Its Comparison in the Current Update; Post-Report Move: Shares Finish 2.29% Lower at the CloseFull Year Guidance - vinanet.vn
Cadrenal Therapeutics (CVKD) Falls 4.28% to $1.79, Pressing Against Key SupportFibonacci Entry Signals - vinanet.vn
Avoiding Lag: Real-Time Signals in (CVKD) Movement - Stock Traders Daily
Cadrenal Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cadrenal Maintained at Buy as Partnership-Focused Strategy Supports Unchanged $13 Price Target - TipRanks
Cadrenal Therapeutics Q2 Results: Net Loss Narrows To $3.3 Million - scanx.trade
Cadrenal to seek FDA pediatric designation for tecarfarin - scanx.trade
Cadrenal Therapeutics data on CAD-1005 accepted for ISTH presentation - scanx.trade
PNC Financial Services Group, Inc. Acquires New Stake in Cadrenal Therapeutics Inc (CVKD) - GuruFocus
Cadrenal Therapeutics appoints John P. Sharp as interim CFO - scanx.trade
Cadrenal Therapeutics reports Q2 2026 net loss of $3.3M; cash runway into Q1 2027 - TradingView
Cadrenal CAD-1005 data show more than 25% absolute drop in clot events - Stock Titan
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process - Yahoo Finance
Cadrenal Therapeutics (CVKD) Q1 2026 Earnings: Wider-Than-Expected Loss Buffer Despite Stock DipEstimate Dispersion - Vinanet
Cadrenal Therapeutics (CVKD) Slides 7.5% to $1.84 — Testing Critical Support at $1.75Passive Flow - dars.gov.et
Cadrenal Therapeutics Inc (CVKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a shareEarnings Preview - TradingView
Cadrenal Therapeutics (CVKD): PNC discloses 8.13% beneficial stake for client - Stock Titan
CVKD | Cadrenal Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Cadrenal Therapeutics (CVKD) Slips 2.49% to $1.96 as Shares Test Range-Bound SupportAI Trade Signals - dars.gov.et
CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy - Smartkarma
Cadrenal expands CAD-1005 development to two indications - Investing.com
Cadrenal expands CAD-1005 development to two indications By Investing.com - Investing.com India
Cadrenal Therapeutics Highlights CAD-1005 as Dual-Indication 12-LOX Inhibitor for HIT and CSA-AKI Following Competing Trial Failure - Quiver Quantitative
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation - Yahoo Finance
Cadrenal Therapeutics (CVKD) Drops 3.8%, Approaches Critical $1.91 SupportMean Reversion Trade - dars.gov.et
Cadrenal Therapeutics Inc (CVKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cadrenal Therapeutics Inc (CVKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cadrenal Therapeutics Inc (CVKD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CVKD|Cadrenal Therapeutics Inc|Price:1.830|Chg%:-0.030 - TradingKey
Cadrenal Therapeutics Inc (CVKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cadrenal Therapeutics Inc (CVKD) Institutional Confidence - TradingKey
Cadrenal Therapeutics Inc (CVKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CVKD|Cadrenal Therapeutics Inc|Price:2.045|Chg%:-0.015 - TradingKey
Cadrenal Therapeutics Inc (CVKD) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
TradingKey - TradingKey
Cadrenal Therapeutics Inc (CVKD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cadrenal Therapeutics Market Sentiment - Benzinga España
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):